BioXcel Therapeutics files clinical trial application for development of BXCL701 in tNEPC
BioXcel Therapeutics announced that it has filed a CTA with the U.K. health authorities for its lead immuno-oncology asset, BXCL701, an orally-available small molecule immune-modulator with dual mechanisms of action, in combination with pembrolizumab (Keytrudaź), a checkpoint inhibitor, in tNEPC. March 25, 2019